Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2010-07-27

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-10-0324PMID 20663931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

  2010cited by this paper
• CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

  2008cited by this paper
• E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8

  2008cited by this paper
• Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

  2006cited by this paper
• Cyclin-dependent kinase pathways as targets for cancer treatment.

  2006cited by this paper
• Drug development in oncology: classical cytotoxics and molecularly targeted agents.

  2006cited by this paper
• Unmasking the Redundancy Between Cdk1 and Cdk2 at G2 Phase in Human Cancer Cell Lines

  2006cited by this paper
• Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

  2005cited by this paper
• Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control

  2002cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

  2002cited by this paper
• S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human Cells

  2001cited by this paper
• Cell cycle regulation and RNA polymerase II.

  2000cited by this paper
• Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

  1999cited by this paper
• Regulation of the cell cycle by the Rb tumor suppressor family.

  1998cited by this paper
• Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

  1994cited by this paper
• Protein kinases and cell cycle control.

  1994cited by this paper
• Growth factor-regulated G1 cyclins.

  1994cited by this paper
• The cell cycle and the retinoblastoma protein family

  1994cited by this paper
• Distinct roles for cyclin-dependent kinases in cell cycle control.

  1993cited by this paper

• Molecular glue degraders: Rational design, specificity engineering, and advanced delivery

  2026cites this paper
• In Vitro and In Silico Assessment of the Anticancer Potential of Ethyl Acetate/Water Extract from the Leaves of Cotinus coggygria Scop. in HepG2 Human Hepatocarcinoma Cells

  2026cites this paper
• CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction

  2026cites this paper
• Dinaciclib reduces MCL-1 levels and triggers apoptosis in adult T-cell leukemia/lymphoma.

  2026cites this paper
• Exploring imidazo[1,2-a]pyridine hybrids in cancer therapy: ADMET profiling, molecular docking, MD simulations and DFT calculations.

  2026cites this paper
• New 2-benzylideneamino-4,5-diphenylfuran-3‑carbonitrile derivatives and their benzylamino analogues: Synthesis, in vitro cytotoxicity, protein kinase inhibitory activity and in silico insights.

  2025cites this paper
• Design, synthesis, biological and computational evaluation of novel S/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy.

  2025cites this paper
• Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues

  2025cites this paper
• Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors.

  2025cites this paper
• Age‐Dependent Regulation of Hippocampal Inflammation by the Mitochondrial Translocator Protein in Mice

  2025cites this paper
• CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridine.

  2025cites this paper
• Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia

  2025cites this paper
• Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment.

  2025cites this paper
• Synthesis of novel series of pyrazolo[1,5-a]pyrimidines target PIM-1 kinase

  2025cites this paper
• Targeting a Tau Kinase Cdk5, Cyclin-Dependent Kinase: A Blood-Based Diagnostic Marker and Therapeutic Earmark for Alzheimer’s Disease

  2025cites this paper
• Tahoe-100M: A Giga-Scale Single-Cell Perturbation Atlas for Context-Dependent Gene Function and Cellular Modeling

  2025cites this paper
• Characterization and Inhibition of Human Hexokinase Domain Containing Protein 1 Reveals an Enzyme with Unique Catalytic and Regulatory Traits.

  2025cites this paper
• Metabolic-associated fatty liver disease (MAFLD) promotes the progression of hepatocellular carcinoma by enhancing KIF20A expression.

  2025cites this paper
• Cyclin-dependent kinase 1 (CDK1) in cancers: from upstream regulation to downstream substrates and therapeutic inhibitors.

  2025cites this paper
• Current progress in targeting mitotic kinases in PDAC.

  2025cites this paper
• Combining anti-gene γPNA with small molecules and RNA inhibitors: A strategy to enhance anti-tumor efficacy

  2025cites this paper
• Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer.

  2025cites this paper
• Dual / bifunctional targeting of bromodomain and extra-terminal (BET) proteins: Expanding the paradigm of epigenetic drug discovery.

  2025cites this paper
• Beyond Inhibition: Recent Advances of Heterobifunctional Molecules Targeting CDK9.

  2025cites this paper
• Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

  2025cites this paper
• Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.

  2024cites this paper
• Cell cycle machinery in oncology: A comprehensive review of therapeutic targets

  2024cites this paper
• Cyclin-dependent Kinase 5 and Neurodegenerative Diseases

  2024cites this paper
• The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study

  2024cites this paper
• CDK9 inhibition as an effective therapy for small cell lung cancer

  2024cites this paper
• Crystallographic fragment screening of CDK2-cyclin A: FragLites map sites of protein-protein interaction

  2024cites this paper
• Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma

  2024cites this paper
• PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro

  2024cites this paper
• Trailblazing real-world-data to confront hepatocellular carcinoma – disinterring repurposable drugs by amalgamating avant-garde stratagems

  2024cites this paper
• The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescence

  2024cites this paper
• L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity

  2024cites this paper
• A Revision of Herpes Simplex Virus Type 1 Transcription: First, Repress; Then, Express

  2024cites this paper
• The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer

  2024cites this paper
• Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

  2024cites this paper
• Integration of Transcriptomics, Proteomics and Loss-of-function Screening Reveals WEE1 as a Target for Combination with Dasatinib against Proneural Glioblastoma.

  2024cites this paper
• Expression analysis, molecular docking and molecular dynamics simulations to identify potential BTK inhibitors: strategy for targeting pan-cancer

  2024influential citation
• CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma.

  2024cites this paper
• A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

  2024cites this paper
• The Wnt/Pyruvate kinase, Muscle axis plays an essential role in the differentiation of mouse neuroblastoma cells.

  2024cites this paper
• Molecular mechanism of PARP inhibitor resistance

  2024cites this paper
• Physiological and pathological roles of the transcriptional kinases CDK12 and CDK13 in the central nervous system

  2024cites this paper
• CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer

  2024cites this paper
• A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

  2024cites this paper
• NELF and PAF1C complexes are core transcriptional machineries controlling colon cancer stemness

  2024cites this paper
• Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer

  2024cites this paper
• CDK11, a splicing-associated kinase regulating gene expression.

  2024cites this paper
• Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases.

  2024cites this paper
• Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors

  2024cites this paper
• BCL-2 inhibition in acute myeloid leukemia: resistance and combinations

  2024cites this paper
• A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of metastatic small-cell lung cancer

  2024cites this paper
• Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia

  2024cites this paper
• ClonoScreen3D - a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma.

  2024cites this paper
• Aberrant RNA polymerase initiation and processivity on the genome of a herpes simplex virus 1 mutant lacking ICP27

  2024cites this paper
• Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.

  2024cites this paper
• The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

  2024cites this paper
• CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.

  2024cites this paper
• Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach.

  2024cites this paper
• Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer

  2024influential citation
• FOXK2 amplification promotes breast cancer development and chemoresistance.

  2024cites this paper
• The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells

  2024cites this paper
• A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

  2024influential citation
• Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

  2024cites this paper
• Rhodium-Catalyzed Asymmetric Reductive Hydroformylation of α-Substituted Enamides

  2024cites this paper
• Centrosomes and associated proteins in pathogenesis and treatment of breast cancer

  2024cites this paper
• MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

  2024cites this paper
• Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

  2024influential citation
• Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer

  2023cites this paper
• Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines

  2023cites this paper
• One-Pot Three-Component Synthesis of Novel Pyrano[3,2-E]Pyrazaolo[1,5-A]Pyrimidines and Investigation of Their Biological Activities

  2023cites this paper
• Synthesis of new sulfapyrimidine and pyrazolo[1,5-a]pyrimidine derivatives

  2023cites this paper
• Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition

  2023cites this paper
• Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies.

  2023cites this paper
• Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway

  2023cites this paper
• A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases.

  2023cites this paper
• Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions

  2023cites this paper
• Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia

  2023cites this paper
• CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells.

  2023cites this paper
• Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics.

  2023cites this paper
• Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach

  2023cites this paper
• Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment

  2023cites this paper
• Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis – a review of current evidence

  2023cites this paper
• Structural basis of CDK3 activation by cyclin E1 and inhibition by dinaciclib.

  2023cites this paper
• Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response

  2023cites this paper
• ClonoScreen3D: a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma

  2023cites this paper
• Design and Synthesis of New bis-oxindole and Spiro(triazole-oxindole) as CDK4 Inhibitors with Potent Anti-breast Cancer Activity.

  2023cites this paper
• Resistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases

  2023cites this paper
• The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches

  2023cites this paper
• Preparation of Some New Pyrazolo[1,5‐a]pyrimidines and Evaluation of Their Antioxidant, Antibacterial (MIC and ZOI) Activities, and Cytotoxic Effect on MCF‐7 Cell Lines

  2023cites this paper
• Design principles for cyclin K molecular glue degraders

  2023cites this paper
• In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents

  2023cites this paper
• Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma

  2023cites this paper
• Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023)

  2023cites this paper
• MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma

  2023influential citation
• Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients

  2023cites this paper
• Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2).

  2023cites this paper